Oncology PracticeTrial matches pediatric cancer patients to targeted therapiesMay 31, 2019Sarcoma & GISTPediatricsRenal Cell CarcinomaCNS/Brain CancerGenitourinary CancerPediatric Neuroblastoma
Oncology PracticeEqual access to care for black men lowers risk of prostate cancer-specific mortalityMay 24, 2019Genitourinary Cancer
Enzalutamide in castration-sensitive prostate cancer and ctDNA to monitor early colorectal cancerMay 22, 2019Genitourinary CancerGastroenterologyGastrointestinal Cancer
Oncology PracticeARCHES: Enzalutamide improves mHSPC survival regardless of baseline PSAMay 6, 2019Genitourinary Cancer
Hospital Physician: Hematology/OncologyManagement of Castration-Resistant Prostate CancerApril 3, 2019Genitourinary Cancer
Oncology PracticePembrolizumab/lenvatinib active against urothelial carcinomaMarch 11, 2019Genitourinary CancerImmuno-oncology
Oncology PracticeSEER data: Abiraterone acetate may up mortality risk in prostate cancer patients with CVDMarch 1, 2019Genitourinary Cancer
Oncology PracticeSperm counts largely stable after adjuvant treatment of clinical stage I testicular cancerMarch 1, 2019Genitourinary CancerPatient & Survivor Care
Oncology PracticeEnzalutamide boosts ADT benefit in metastatic hormone-sensitive prostate cancerFebruary 26, 2019Genitourinary Cancer
Oncology PracticeModel shows nivolumab plus ipilimumab cost effective in mRCCFebruary 25, 2019Practice ManagementGenitourinary CancerRenal Cell CarcinomaImmuno-oncologyBusiness of Medicine
Oncology PracticeFirst-line avelumab/axitinib for RCC benefits wide range of patientsFebruary 21, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Oncology PracticeARAMIS: Darolutamide shines in nonmetastatic CRPCFebruary 20, 2019Genitourinary Cancer
Oncology PracticeSurvival of patients with mCRPC on hormone therapy differs by raceFebruary 13, 2019Genitourinary Cancer
Oncology PracticePembrolizumab-axitinib nearly halves risk of death in RCCFebruary 12, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Oncology PracticeRadioligand is highly active in metastatic castrate-resistant prostate cancerFebruary 12, 2019Genitourinary Cancer
